Streetbeat News

Products Services

MDWD

MDXG

MediWound Ltd. (NASDAQ:MDWD) has entered into a research collaboration agreement with MIMEDX Group, Inc (NASDAQ:MDXG) for the EscharEx Phase III study in venous leg ulcers (VLUs). MIMEDX will provide its placental tissue allograft EPIFIX to be used during the wound healing phase of the study. The aim is to maintain consistency among study subjects and optimize the potential for complete healing throughout the study duration.

Portfolio Pulse from Happy Mohamed

August 15, 2023 | 8:09 pm

MDWD

MediWound Ltd. (NASDAQ:MDWD) has announced a research collaboration agreement with Mölnlycke for its upcoming Phase III study of EscharEx in venous leg ulcers (VLUs). Mölnlycke will provide its Mepilex Up, Exufiber, and Exufiber Ag dressings for the wound healing phase of the study. The study aims to evaluate the efficacy and safety of EscharEx in the debridement of chronic wounds.

Portfolio Pulse from Happy Mohamed

August 15, 2023 | 8:08 pm

HII

Huntington Ingalls Industries' (NYSE:HII) Ingalls Shipbuilding division has successfully launched the Navy's third Flight III Arleigh Burke-class guided missile destroyer, Ted Stevens (DDG 128). Ingalls has delivered 35 Arleigh Burke-class destroyers to the U.S. Navy, including the first Flight III, Jack H. Lucas (DDG 125), in June of this year. The company has four Flight IIIs currently under construction and was awarded an additional six destroyers earlier this month.

Portfolio Pulse from Happy Mohamed

August 15, 2023 | 8:05 pm

ANGO

AngioDynamics has received FDA Breakthrough Device Designation for its AngioVac System, a non-surgical solution for the removal of right heart vegetation. This designation will expedite the development and review process of the device.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 8:03 pm

DSGN

RBC Capital Market has downgraded Design Therapeutics Inc (NASDAQ:DSGN) from Outperform to Sector Perform with a price target of $7, down from $23. This follows the company's announcement of initial results from its Phase 1 clinical trial of DT-216 in patients with Friedrich ataxia and plans to reformulate the drug due to injection site reactions. RBC analysts see potential in the modified versions of DT-216 but are adopting a wait-and-see approach due to extended development timelines and inherent risks.

Portfolio Pulse from Vandana Singh

August 15, 2023 | 7:32 pm

DBCCF

TLRY

Decibel Cannabis Co Inc. (OTCQB:DBCCF) and Tilray (NASDAQ:TLRY) are leading the pre-roll cannabis market in Canada, according to data from Hifyre. Decibel commands a 16% segment share, with pre-rolls driving 65% of its total sales in 2Q23. Tilray holds a 13.8% share, bolstered by its acquisition of HEXO. Decibel's infused pre-rolls have tripled its sales year-on-year for 2Q23, while Tilray's brands have experienced modest share erosion.

Portfolio Pulse from Nicolás Jose Rodriguez

August 15, 2023 | 7:13 pm

PAYO

Payoneer Singapore has secured a Major Payment Institution license, which will enhance its in-market product and service offerings. This complements Payoneer's suite of global licenses.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 7:05 pm

UBSFF

Ubisoft Entertainment SA has announced that its game, Assassin's Creed Mirage, will be launching a week earlier than planned, on October 5. The game has reached the 'gone gold' stage, indicating the completion of the launch version. Ubisoft has also partnered with Spanish company OWO to create a haptic feedback vest for the game, which is now available for pre-order at $588.

Portfolio Pulse from Franca Quarneti

August 15, 2023 | 6:36 pm

BIOL

Biolase has been granted a U.S. patent titled 'Dental system and method (including at least one laser, one processor, and one storage medium)'. This could potentially strengthen the company's intellectual property portfolio and provide a competitive edge in the dental equipment market.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 6:10 pm

SONY

Sony Group Corp's Insomniac Games has announced new accessibility features for 'Marvel's Spider-Man 2' to enhance the gaming experience for gamers with disabilities. These features include the ability to slow down gameplay and screen reader support. More details are expected to be disclosed closer to the game's launch on Oct. 20. In July, PlayStation started pre-orders for its Access Controller, a customizable PS5 controller for players with disabilities.

Portfolio Pulse from Franca Quarneti

August 15, 2023 | 5:22 pm